ArticleInternational journal of molecular sciences2018
The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 72 citations in OpenAlex.
- Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.Journal of atherosclerosis and thrombosis · 2023Trial
- Extracellular Vesicle-Encapsulated Small RNAs From Clostridium Butyricum Modulate Host Intestinal Lipid Metabolism.Journal of extracellular vesicles · 2026Article
- Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- PERSPECTIVE: Beyond the GH-IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights.Endocrine connections · 2026Article
- Adverse event profiles of fenofibrate and gemfibrozil: a retrospective comparative study and literature synthesis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hepatocyte PPARα Is Essential for Triglyceride-Lowering Effect of Pemafibrate.International journal of molecular sciences · 2026Article
- Role of Circulating Lipids in Mediating the Diabetogenic Effect of Obesity.Biomedicines · 2025Article
- Triglycerides, Glucose Metabolism, and Type 2 Diabetes.International journal of molecular sciences · 2025Review
- Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats.BMC gastroenterology · 2025Article
- Lipids dysregulation in diseases: core concepts, targets and treatment strategies.Lipids in health and disease · 2025Review
- The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.Current obesity reports · 2025Review
- Effects of supplementation with vitamin DFrontiers in veterinary science · 2025Article
- Intestinal epithelial cell NCoR deficiency ameliorates obesity and metabolic syndrome.Acta pharmaceutica Sinica. B · 2024Article
- FGF21 mediating the Sex-dependent Response to Dietary Macronutrients.The Journal of clinical endocrinology and metabolism · 2024Review
- Morin Prevents Non-Alcoholic Hepatic Steatosis in Obese Rats by Targeting the Peroxisome Proliferator-Activated Receptor Alpha (PPARα).Life (Basel, Switzerland) · 2024Article
- Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives.International journal of molecular sciences · 2024Review
- Homeostasis Model Assessment for Insulin Resistance Mediates the Positive Association of Triglycerides with Diabetes.Diagnostics (Basel, Switzerland) · 2024Article
- Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD.Frontiers in endocrinology · 2024Article
- Article
- Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.Clinical and experimental hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptor α (PPARα) is a therapeutic target for hyperlipidemia. Pemafibrate (K-877) is a new selective PPARα modulator activating PPARα transcriptional activity. To determine the effects of pemafibrate on diet-induced obesity, wild-type mice were fed a high-fat diet (HFD) containing pemafibrate for 12 weeks. Like fenofibrate, pemafibrate significantly suppressed HFD-induced body weight gain; decreased plasma glucose, insulin and triglyceride (TG) levels; and increased plasma fibroblast growth factor 21 (FGF21). However, compared to the dose of fenofibrate, a relatively low dose of pemafibrate showed these effects. Pemafibrate activated PPARα transcriptional activity in the liver, increasing both hepatic expression and plasma levels of FGF21. Additionally, pemafibrate increased the expression of genes involved in thermogenesis and fatty acid oxidation, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.